1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Optic Neuritis - Drugs In Development, 2022, provides an overview of the Optic Neuritis (Ophthalmology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Optic neuritis is an inflammation of the optic nerve, the bundle of nerve fibers that transmits visual information from eye to brain. Symptoms include pain, vision loss, dyschromatopsia, Uhthoff’s phenomenon and flashing lights. Risk factors include age and genetic mutations.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Optic Neuritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Optic Neuritis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Optic Neuritis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Optic Neuritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 7 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.
Optic Neuritis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Optic Neuritis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Optic Neuritis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Optic Neuritis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Optic Neuritis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Optic Neuritis (Ophthalmology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Optic Neuritis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Optic Neuritis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Optic Neuritis - Overview
- Optic Neuritis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Optic Neuritis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Optic Neuritis - Companies Involved in Therapeutics Development
- Cresence AS
- EnhanX Biopharm Inc
- Find Therapeutics Inc
- Japan Innovative Therapeutics Inc
- Mitochon Pharmaceuticals Inc
- Noveome Biotherapeutics Inc
- Oculis SA
- Parvus Therapeutics Inc
- ReNetX Bio
- SanBio Co Ltd
- Trethera Corp
- Worphmed Srl
- Optic Neuritis - Drug Profiles
- AXER-204 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- EGF1-48 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ENX-201 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapies for Glaucoma, Optic Neuritis and Retinitis Pigmentosa - Drug Profile
- Product Description
- Mechanism Of Action
- gypenoside - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Innovative Therapy - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- melatonin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MP-101 - Drug Profile
- Product Description
- Mechanism Of Action
- OCS-05 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- OT-1602 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Optic Neuritis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ST-266 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TRE-515 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Vaccine for Optic Neuritis - Drug Profile
- Product Description
- Mechanism Of Action
- Optic Neuritis - Dormant Projects
- Optic Neuritis - Discontinued Products
- Optic Neuritis - Product Development Milestones
- Featured News & Press Releases
- Aug 09, 2022: Trethera announces FDA Orphan Drug Designation granted to TRE-515 for the treatment of demyelinating optic neuritis
- Oct 21, 2020: Noveome Biotherapeutics announces publication of preclinical results demonstrating the neuroprotective properties of amnion-derived multipotent pCells in spinal cord and retinal ganglion cells
- May 15, 2019: Bionure appoints Dr. Lucia Septien as chief medical officer
- May 09, 2019: Noveome Biotherapeutics announces publication of further preclinical results supporting the neuroprotective properties of ST266 in retinal ganglion cells
- May 07, 2019: Neuroprotection Biotech Bionure Reports Successful Phase 1 Study for Lead Candidate BN201
- Oct 09, 2018: Bionure appoints Dr. Laurent Nguyen as CEO
- May 16, 2018: Bionure initiates a Phase 1 clinical trial of its lead compound BN201 in the United Kingdom
- Jan 31, 2017: Noveome Biotherapeutics Publishes Data Demonstrating Anti-inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Optic Neuritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Optic Neuritis - Pipeline by Cresence AS, 2022
- Optic Neuritis - Pipeline by EnhanX Biopharm Inc, 2022
- Optic Neuritis - Pipeline by Find Therapeutics Inc, 2022
- Optic Neuritis - Pipeline by Japan Innovative Therapeutics Inc, 2022
- Optic Neuritis - Pipeline by Mitochon Pharmaceuticals Inc, 2022
- Optic Neuritis - Pipeline by Noveome Biotherapeutics Inc, 2022
- Optic Neuritis - Pipeline by Oculis SA, 2022
- Optic Neuritis - Pipeline by Parvus Therapeutics Inc, 2022
- Optic Neuritis - Pipeline by ReNetX Bio, 2022
- Optic Neuritis - Pipeline by SanBio Co Ltd, 2022
- Optic Neuritis - Pipeline by Trethera Corp, 2022
- Optic Neuritis - Pipeline by Worphmed Srl, 2022
- Optic Neuritis - Dormant Projects, 2022
- Optic Neuritis - Discontinued Products, 2022
- Number of Products under Development for Optic Neuritis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Cresence AS
- EnhanX Biopharm Inc
- Find Therapeutics Inc
- Japan Innovative Therapeutics Inc
- Mitochon Pharmaceuticals Inc
- Noveome Biotherapeutics Inc
- Oculis SA
- Parvus Therapeutics Inc
- ReNetX Bio
- SanBio Co Ltd
- Trethera Corp
- Worphmed Srl
